SCHEMBL4779518

SCHEMBL4779518

Fc1cc2c(cc1Cl)NCCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.41
HTR2C P28335 2/20 0.41
HTR2B P41595 2/20 0.41
KDM4E B2RXH2 3/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 3/20 0.41
ALDH1A1 P00352 3/20 0.41
TDP1 Q9NUW8 3/20 0.41
TP53 P04637 2/20 0.41
ALOX15 P16050 2/20 0.41
HTT P42858 2/20 0.41
HSD17B10 Q99714 2/20 0.41
LMNA P02545 1/20 0.41
THRB P10828 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
AR P10275 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30888660 1.00 HTR2A (0.41) HTR2AHTR2CHTR2BKDM4EMAPT
SCHEMBL30888682 0.93 KDM4E (0.41) HTR2AHTR2CHTR2BKDM4EMAPT
SCHEMBL10913742 0.93 KDM4E (0.41) HTR2AHTR2CHTR2BKDM4EMAPT
SCHEMBL30964480 0.89 HTR2A (0.47) HTR2AHTR2CHTR2BMAPTALDH1A1
SCHEMBL5827521 0.89 HTR2A (0.47) HTR2AHTR2CHTR2BMAPTALDH1A1
SCHEMBL2217869 0.84 MAPT (0.45) KDM4EMAPTGAAALDH1A1TDP1
SCHEMBL11015073 0.84 MAPT (0.44) HTR2AHTR2CHTR2BKDM4EMAPT
SCHEMBL17937412 0.79 MAPT (0.40) KDM4EMAPTGAAALDH1A1TDP1
SCHEMBL17785691 0.78 MAPT (0.42) KDM4EMAPTGAAALDH1A1TDP1
SCHEMBL9510669 0.78 ATM (0.48) KDM4EMAPTGAAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3416633-B1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS UNIV ILLINOIS (US) 2025-07-23 EP disclosed
WO-2024121129-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
US-10456394-B2 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-10-29 US disclosed
US-10456394-B2 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-10-29 US disclosed
US-20190255046-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) 2019-08-22 US disclosed
US-20190255046-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) 2019-08-22 US disclosed
EP-3416633-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS The Board of Trustees of the University of Illinois (US) 2018-12-26 EP disclosed
WO-2017142883-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-08-24 WO disclosed
WO-2017142883-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-08-24 WO disclosed
US-20080139546-A1 Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines WYETH (US) 2008-06-12 US disclosed
WO-2008042735-A1 TETRAHYDROQUINOLINE, INDOLINE, AND RELATED ANILINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES WYETH (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190255046-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS HDAC1, HDAC5, HDAC7 HTR2A 653/4885HTR2C 1025/4885HTR2B 608/4885
US-10456394-B2 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors HDAC1, HDAC5, HDAC7 HTR2A 653/4885HTR2C 1025/4885HTR2B 608/4885
US-20080139546-A1 Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines HTR5A, HTR2C, HTR3A HTR2A 8/4885HTR2C 2/4885HTR2B 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.